| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9579359 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Feb, 2029
(5 years from now) | |
| US10973870 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(5 years from now) | |
| US10729739 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(5 years from now) | |
| US9415085 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
| US10695398 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
Firmagon is owned by Ferring.
Firmagon contains Degarelix Acetate.
Firmagon has a total of 5 drug patents out of which 0 drug patents have expired.
Firmagon was authorised for market use on 24 December, 2008.
Firmagon is available in powder;subcutaneous dosage forms.
Firmagon can be used as treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect, method of treating prostate cancer.
The generics of Firmagon are possible to be released after 27 April, 2032.
Drugs and Companies using DEGARELIX ACETATE ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer
Dosage: POWDER;SUBCUTANEOUS
FIRMAGON family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic